Drug Patents owned by Bausch

1. Drug name - ACANYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504704 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US9078870 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US8663699 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US10624918 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US10137142 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US8895070 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US10220049 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US9561208 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Jun, 2029

(6 years from now)

US8288434 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent Aug, 2029

(6 years from now)

Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Treatment: Treatment of acne vulgaris; topical treatment of acne vulgaris; topical treatment of acne vulgaris in patients 12 years or older; treatment of acne; Treatment of acne; Topical treatment of acne vulgaris in patients 12 years or older; Topical treatment of acne vulgaris; treatment of acne; treatment of acne vulgaris; topical treatment of acne vulgaris; treatment of acne vulgaris; topical treatment of acne vulgaris in patients 12 years or older

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
2.5%;EQ 1.2% BASE GEL;TOPICAL Prescription
3.75%;EQ 1.2% BASE GEL;TOPICAL Prescription

2. Drug name - ALDARA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7696159 BAUSCH Treatment for basal cell carcinoma
Apr, 2024

(1 year, 5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696159

(Pediatric)

BAUSCH Treatment for basal cell carcinoma Oct, 2024

(1 year, 11 months from now)

Drugs and Companies using IMIQUIMOD ingredient

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
5% CREAM;TOPICAL Prescription

3. Drug name - APLENZIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7569610 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7241805 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7649019 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7671094 BAUSCH Bupropion hydrobromide and therapeutic applications Jun, 2026

(3 years from now)

US7572935 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7585897 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7645802 BAUSCH Bupropion hydrobromide and therapeutic applications Jun, 2026

(3 years from now)

US7662407 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

Drugs and Companies using BUPROPION HYDROBROMIDE ingredient

Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
174MG TABLET, EXTENDED RELEASE;ORAL Prescription
348MG TABLET, EXTENDED RELEASE;ORAL Prescription
522MG TABLET, EXTENDED RELEASE;ORAL Prescription

4. Drug name - BRYHALI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration Nov, 2031

(9 years from now)

US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration Nov, 2031

(9 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.01% LOTION;TOPICAL Prescription

5. Drug name - DUOBRII

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration Nov, 2031

(9 years from now)

US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration Nov, 2031

(9 years from now)

US10251895 BAUSCH Topical compositions and methods for treating psoriasis Jun, 2036

(13 years from now)

US10426787 BAUSCH Topical compositions and methods for treating psoriasis Jun, 2036

(13 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.01%;0.045% LOTION;TOPICAL Prescription

6. Drug name - JUBLIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214506 BAUSCH Method for treating onychomycosis Feb, 2026

(3 years from now)

US10828369 BAUSCH Compositions and methods for treating diseases of the nail Jan, 2028

(5 years from now)

US11213519 BAUSCH Compositions and methods for treating diseases of the nail Jan, 2028

(5 years from now)

US9566272 BAUSCH Compositions and methods for treating diseases of the nail Jan, 2028

(5 years from now)

US9877955 BAUSCH Compositions and methods for treating diseases of the nail Jan, 2028

(5 years from now)

US10512640 BAUSCH Compositions and methods for treating diseases of the nail Jan, 2028

(5 years from now)

US10105444 BAUSCH Compositions and methods for treating diseases of the nail Jul, 2030

(7 years from now)

US8039494 BAUSCH Compositions and methods for treating diseases of the nail Jul, 2030

(7 years from now)

US9861698 BAUSCH Compositions and methods for treating diseases of the nail Jul, 2030

(7 years from now)

US8486978 BAUSCH Compositions and methods for treating diseases of the nail Oct, 2030

(8 years from now)

US9302009 BAUSCH Compositions and methods for treating diseases of the nail Oct, 2030

(8 years from now)

US10342875 BAUSCH Stabilized efinaconazole compositions Oct, 2034

(12 years from now)

US10828293 BAUSCH Anti-infective methods, compositions, and devices Oct, 2034

(12 years from now)

US9662394 BAUSCH Stabilized efinaconazole compositions Oct, 2034

(12 years from now)

US10864274 BAUSCH Stabilized efinaconazole formulations Oct, 2034

(12 years from now)

US10478601 BAUSCH Applicator Apr, 2035

(12 years from now)

Drugs and Companies using EFINACONAZOLE ingredient

Treatment: Antimycotic uses, specifically treatment of onychomycosis; Antimycotic uses, specifically treatment of onychomycosis; topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
10% SOLUTION;TOPICAL Prescription

7. Drug name - LOCOID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7981877 BAUSCH Stabilized steroid composition and method for its preparation Jan, 2025

(2 years from now)

US7378405 BAUSCH Stabilized steroid composition and method for its preparation Dec, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
0.1% LOTION;TOPICAL Prescription

8. Drug name - LUZU

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9453006 BAUSCH Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
Sep, 2033

(10 years from now)

US9012484 BAUSCH Crystal and pharmaceutical preparation containing the same crystal
Sep, 2033

(10 years from now)

US9199977 BAUSCH Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
Sep, 2033

(10 years from now)

CN104284662A BAUSCH Crystal And Drug Preparation Comprising This Crystal
Sep, 2018

(4 years ago)

CN104619703A BAUSCH Crystal With Crystallization Habit Modifier And The Drug Composition Through The Crystal For Processing To Obtain The Same
Dec, 2018

(3 years ago)

CN105026390A BAUSCH Crystal Form With Specific Crystallization Habit Modifier And Drug Composition Containing Crystal Form As Active Ingredient
Jun, 2033

(10 years from now)

CN105026390B BAUSCH Crystal Form With Specific Crystallization Habit Modifier And Drug Composition Containing Crystal Form As Active Ingredient
Jun, 2033

(10 years from now)

EP2964641B1 BAUSCH Crystalline Form Having Specific Crystal Habit And Pharmaceutical Composition Containing This Crystalline Form As Active Ingredient
Jun, 2033

(10 years from now)

EP2964641A1 BAUSCH Crystalline Form Having Specific Crystal Habit And Pharmaceutical Composition Containing This Crystalline Form As Active Ingredient
Jun, 2033

(10 years from now)

EP2895165A1 BAUSCH Crystal And Pharmaceutical Preparation Containing The Same Crystal
Sep, 2033

(10 years from now)

EP2895165B1 BAUSCH Crystal And Pharmaceutical Preparation Containing The Same Crystal
Sep, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980931 BAUSCH Method of evaluating pharmaceutical preparation containing luliconazole and index substance Apr, 2034

(11 years from now)

Drugs and Companies using LULICONAZOLE ingredient

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

9. Drug name - SOLODYN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722650 BAUSCH Extended-release minocycline dosage forms Jun, 2025

(2 years from now)

US7790705 BAUSCH Minocycline oral dosage forms for the treatment of acne Jun, 2025

(2 years from now)

US8268804 BAUSCH Minocycline oral dosage forms for the treatment of acne Jun, 2025

(2 years from now)

US8252776 BAUSCH Minocycline oral dosage forms for the treatment of acne Jun, 2025

(2 years from now)

US7919483 BAUSCH Method for the treatment of acne Mar, 2027

(4 years from now)

US7541347 BAUSCH Minocycline oral dosage forms for the treatment of acne Apr, 2027

(4 years from now)

US7544373 BAUSCH Minocycline oral dosage forms for the treatment of acne Apr, 2027

(4 years from now)

US9192615 BAUSCH Method for the treatment of acne and certain dosage forms thereof Nov, 2031

(9 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Treatment: Treatment of acne; Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 45MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
EQ 55MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 65MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 80MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 90MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
EQ 105MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 115MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 135MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

10. Drug name - VANOS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7220424 BAUSCH Compositions and methods for enhancing corticosteroid delivery Jan, 2023

(3 months from now)

US8232264 BAUSCH Compositions and methods for enhancing corticosteroid delivery Mar, 2023

(5 months from now)

Drugs and Companies using FLUOCINONIDE ingredient

Treatment: Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.1% CREAM;TOPICAL Prescription

11. Drug name - XERESE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7223387 BAUSCH Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester Nov, 2022

(a month from now)

Drugs and Companies using ACYCLOVIR; HYDROCORTISONE ingredient

Treatment: New combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolescents (12 years of age and older); combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older)

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
5%;1% CREAM;TOPICAL Prescription

12. Drug name - ZYCLARA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598196 BAUSCH Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy Aug, 2029

(6 years from now)

US10238645 BAUSCH Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts Aug, 2029

(6 years from now)

US8236816 BAUSCH 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod Dec, 2029

(7 years from now)

US8299109 BAUSCH Method of treating actinic keratosis with 3.75% imiquimod cream Dec, 2029

(7 years from now)

US10238644 BAUSCH 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod Dec, 2029

(7 years from now)

US8222270 BAUSCH 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod Dec, 2029

(7 years from now)

US10918635 BAUSCH Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts Apr, 2030

(7 years from now)

US11202752 BAUSCH Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy Apr, 2030

(7 years from now)

Drugs and Companies using IMIQUIMOD ingredient

Treatment: Treatment of genital warts; treatment of perianal warts; Treatment of actinic keratosis; Treatment of perianal warts; treatment of genital warts

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
2.5% CREAM;TOPICAL Prescription
3.75% CREAM;TOPICAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.